

**ISEC HEALTHCARE LTD.**  
(Company Registration No. 201400185H)  
(Incorporated in Singapore)  
(the “**Company**”)

**MINUTES OF ANNUAL GENERAL MEETING**

**PLACE** : Hotel Royal, 36 Newton Road, Singapore 307964

**DATE** : Wednesday, 29 April 2026

**TIME** : 10.00 a.m.

**PRESENT** : As set out in the attendance records maintained by the Company

**CHAIRMAN** : Mr Chong Weng Hoe

**QUORUM AND INTRODUCTION**

The Chairman called the Annual General Meeting (“**AGM**” or “**Meeting**”) to order at 10.00 a.m.. As a quorum was present, the Chairman declared the Meeting open.

The Chairman introduced the Directors, Chief Executive Officer (“**CEO**”), External Auditors and Sponsors present.

**PRESENTATION TO SHAREHOLDERS**

The Meeting began with a presentation by the CEO, Dr Wong Jun Shyan on the following items:

1. Business Overview;
2. Financial Highlights;
3. Corporate Developments; and
4. Outlook.

The AGM presentation slides was announced via SGXNet and published on the Company’s website on 29 April 2026 after trading hours.

**NOTICE OF MEETING**

The Chairman took the Notice of AGM issued on 14 April 2026 as read.

**APPOINTING CHAIRMAN OF MEETING AS PROXY AND POLL VOTING**

The Chairman informed the Meeting that he had been appointed by some shareholders as proxy and would be voting in accordance with their instructions.

He informed the shareholders that in compliance with the listing rules of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”), the voting of all proposed resolutions will be by poll. He accordingly directed that polling be conducted using a wireless handheld device.

Agile 8 Advisory Pte. Ltd. and Boardroom Corporate & Advisory Services Pte. Ltd. were appointed as Scrutineer and Polling Agent respectively for the purpose of the poll.

## **SUBMISSION OF QUESTIONS**

The Chairman informed the Meeting that there were no questions received from shareholders in advance on the agenda items.

The Chairman further informed the shareholders that they were allowed to raise questions after the relevant resolutions have been proposed.

## **ORDINARY BUSINESS:**

### **Ordinary Resolution 1 – Adoption of Directors’ Statement and Audited Financial Statements for the financial year ended 31 December 2025 together with the Independent Auditor’s Report**

The first resolution was to receive and adopt the Directors’ Statement and the Audited Financial Statements of the Company for the financial year ended 31 December 2025, together with the Independent Auditors’ Report.

The Chairman proposed the motion to pass the following resolution:

“That the Directors’ Statement and the Audited Financial Statements for the financial year ended 31 December 2025 together with the Independent Auditor’s Report be received and adopted.”

The Meeting was opened to the floor for questions. A summary of the ensuing exchange of key salient questions and answers between the Directors, Management and certain shareholders were set out below:

#### **Question 1**

**Regarding the recent Q1 results and gross profit margin, would the current cost structure continue to increase going forward?**

#### **Company’s Response**

The CEO responded that the current cost structure increase may continue for some time as the Group is still in an expansionary phase. He explained that not all new centres opened over the past two years have achieved their optimal margins yet, as some newly opened centres have just reached breakeven.

He further shared that, in line with the Group’s expansion plans, newly recruited doctors are typically provided with a guaranteed remuneration package. Hence, there will be some gestation period before these new doctors can generate revenue exceeding their guaranteed remuneration. Therefore, it was expected that the related costs would continue to affect the Group’s cost of sales and overall profit margins.

Nevertheless, the CEO emphasised that management views this situation as temporary and expects margins to improve progressively as each new centres mature and contribute meaningfully to the Group’s overall performance. He also noted that the Group continues to remain among the better-performing healthcare players in the market in terms of profit-after-tax margin when compared with its industry peers.

## **Question 2**

**Regarding the introduction of national health insurance in Malaysia, how would it impact the Company?**

### **Company's Response**

The CEO responded that, to the best of the Company's knowledge, the Malaysian Government has yet to implement a national health insurance scheme. There has not been any further announcement or clarity on the matter. As such, without further details on the structure and cost implications of the proposed insurance scheme, the Company would not be able to comment on any potential impact.

However, the CEO further shared that approximately 30% to 40% of patients in Malaysia are currently partially insured under personal insurance. Based on the information presently available, the Company does not expect any significant changes to its business operations for now.

## **Question 3**

**Malaysia's current key healthcare payment model is the diagnosis-related payment model. How does this impact the Company?**

### **Company's Response**

The CEO responded that the Company does not expect the diagnosis-related payment model, or Diagnosis-Related Group ("DRG"), in Malaysia to have a significant impact on its operations and in fact, welcomes the proposed implementation. He explained that under this payment model, healthcare providers would receive a fixed payment based on the diagnosis or treatment provided. As such, if doctors are able to complete the treatment efficiently and without complications, costs can be managed effectively under the fixed payment structure.

The CEO further explained that the DRG model would mainly impact inexperienced doctors or cases involving complications, where additional costs arising from complications may need to be borne by the healthcare provider. Therefore, this would affect their profit margins. He noted that the current Group's doctors were capable and experienced, and the occurrence of such complications is very low. In this regard, he added that the Company continues to maintain stringent hiring requirements for every new doctor to ensure high level of standards.

## **Question 4**

**Are there any medical policy changes in Malaysia and Singapore moving forward would affect the Company?**

### **Company's Response**

The CEO responded that the Company is currently not aware of any significant medical policy changes in Malaysia or Singapore in the short term that would materially affect the Group's operations. He added that any future regulatory changes could potentially be beneficial, especially regularising the healthcare industry, which includes facilitating medical practitioners from Singapore to register or practise in Malaysia. He also noted that there are currently no major developments apart from the diagnosis-related payment model, or DRG, changes in Malaysia which had been highlighted earlier.

Dr Lee Hung Ming added that rising healthcare costs in Singapore remain a key concern going forward and patients are generally encouraged to seek treatment at public healthcare institutions due to lower costs. He further shared that approximately 30% of the Group's patients relate to cataract services, including surgeries which are generally covered by insurance, while another 30% relates to refractive procedures such as LASIK and SMILE Pro, of which may also involve certain degree of insurance coverage. However, the remaining outpatient services are generally not covered by medical insurance. Overall, the policy and insurance-related developments may have some impact on the Group's operations but, were not expected to be significant for now.

### **Question 5**

**I would like to understand more about the amount of capital expenditure as the Company is currently undergoing expansion. Could Management provide more details on the centres incurring such expenditure?**

### **Company's Response**

The CEO responded that the Group has set aside approximately RM60 million for future potential capital expenditure this year, including renovation works for new medical centre in KL and new centres set-up.

The CEO explained that, as part of the Group's expansion plans, the Group had acquired strata-title and entered into partnerships with other medical operators to develop a new 14-storey medical centre in KL, where certain portions would be shared with the partners. The Group would co-own selected areas of the property, including the car park facilities and portions of the ground floor common areas allocated for spaces available for plans like cafés and convenience stores, which are expected to generate additional recurring income streams. He added that the Group's existing centre in KL is currently on lease terms incurring annual rental expenses of approximately RM1.5 million to RM2 million, and management believes that owning part of the premises would provide greater operational security and long-term stability.

The CEO added that part of the revenue generated from these common areas would be utilised to offset building maintenance costs. Due to local regulatory requirements, any surplus funds may not be freely distributed. Nevertheless, the arrangement would reduce the need for the Group to incur substantial maintenance-related capital outlay over the building tenure of approximately 99 years.

In addition, the CEO shared that the expansion could increase the Group's operational capacity by approximately three times compared to the existing centre.

The Chairman added that the expansion would require financing support and that the Company intends to utilise a combination of bank borrowings and internal cash resources to fund the capital expenditure. He explained that the Company intends to maintain a prudent financing approach by taking on sufficient, but not excessive, borrowings in order to minimise interest costs. Approximately half of the capital expenditure is expected to be funded through loans, with the remaining portion funded through internal cash resources.

### **Question 6**

**How much has been spent to date for the new KL centre?**

### **Company's Response**

The CEO responded that a significant portion of the project cost involving the acquisition of strata title of the new KL centre is currently being financed through bank borrowings. He further shared that the Group planned to obtain an additional loan facility of up to approximately RM15 million post-acquisition.

The CEO explained that the Group's existing cash reserves were currently being utilised for renovation works and the purchase of new equipment. He added that Management believes this represents a prudent financing approach, as relying excessively on borrowings may not be financially optimal, while maintaining an appropriate level of leverage remains important. As such, the Group intends to maintain a balanced funding structure between internal cash resources and external financing.

The CEO further added that the current approach represents a short-term dilution of returns, as the Group is reinvesting its profits into future growth and expansion initiatives rather than prioritising dividend distributions. He added that external analysts generally view this reinvestment strategy positively as part of the Group's long-term growth plans. The CEO further shared that the Group wished to relocate to the new KL centre premises as early as end of August 2026, provided if the renovation works and necessary operating license can be ready by then.

### **Question 7**

**How much capital expenditure is expected to be incurred for the new Batu Pahat eye centre?**

#### **Company's Response**

The CEO responded that the cost of establishing a new eye centre in Malaysia is estimated to be approximately RM4 million to RM5 million. He explained that the Group currently adopts a funding structure comprising approximately 50% loans and 50% cash for its expansion projects. He added that this is one of the reasons the Company intends to retain cash reserves to support its future expansion plans.

### **Question 8**

**For the Klang centre, has the Company incurred additional capital expenditure?**

#### **Company's Response**

The CEO responded that the Klang centre was already operational and the related capital expenditure has been disbursed.

As there were no further questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 1</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	447,981,013	447,981,013	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 1 carried.

### **Ordinary Resolution 2 – Declaration of Final Tax Exempt (One-Tier) Dividend**

The Chairman said that the Board has recommended a final tax exempt (one-tier) dividend of 0.58 Singapore cents per ordinary share for the financial year ended 31 December 2025.

The Chairman proposed the motion to pass the following resolution:

“That the payment of a final tax exempt (one-tier) dividend of 0.58 Singapore cents per ordinary share for the financial year ended 31 December 2025 be approved.”

Minutes of Annual General Meeting held on 29 April 2026

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 2</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	447,981,013	447,981,013	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 2 carried.

### **Ordinary Resolution 3 - Re-election Mr Chen Bang as a Director of the Company**

Mr Chen Bang who was retiring as a Director of the Company pursuant to Regulation 117 of the Company's Constitution had indicated his consent to continue in office.

The Chairman proposed the motion to pass the following resolution:

"That Mr Chen Bang be re-elected as a Director of the Company."

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 3</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	104,547,223	104,547,223	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 3 carried.

### **Ordinary Resolution 4 - Re-election Mr Li Li as a Director of the Company**

Mr Li Li who was retiring as a Director of the Company pursuant to Regulation 117 of the Company's Constitution had indicated his consent to continue in office.

The Chairman proposed the motion to pass the following resolution:

"That Mr Li Li be re-elected as a Director of the Company."

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 4</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	104,547,223	104,547,223	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 4 carried.

**Ordinary Resolution 5 – Approval of Directors’ fees of S\$120,000 for the financial year ending 31 December 2026, payable quarterly in arrears**

The Chairman sought shareholders’ approval to pay the amount of S\$120,000 as Directors’ fees for the financial year ending 31 December 2026, payable quarterly in arrears.

The Chairman proposed the motion to pass the following resolution:

“That the amount of S\$120,000 as Directors’ fees for the financial year ending 31 December 2026 be approved for payment, payable quarterly in arrears.”

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 5</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	447,731,013	447,731,013	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 5 carried.

**Ordinary Resolution 6 – Re-appointment of Forvis Mazars LLP as the Independent Auditors**

Ordinary Resolution 6 was to approve the re-appointment of Forvis Mazars LLP as the Independent Auditors of the Company and to authorise the Directors to fix their remuneration.

Forvis Mazars LLP had expressed their willingness to continue in office.

The Chairman proposed the motion to pass the following resolution:

“That Forvis Mazars LLP be re-appointed as the Independent Auditors of the Company until the conclusion of the next annual general meeting and that the Directors of the Company be authorised to fix their remuneration.”

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 6</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	447,721,013	447,721,013	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 6 carried.

**ANY OTHER ORDINARY BUSINESS**

As no notice of any other business had been received by the Secretary, the Meeting proceeded to deal with the special business of the Meeting.

**SPECIAL BUSINESS:**

**Ordinary Resolution 7 – Authority to allot and issue shares**

Ordinary Resolution 7 was to authorise the Directors to allot and issue shares and to make or grant instruments convertible into shares pursuant to Section 161 of the Companies Act 1967 and Rule 806 of the SGX-ST Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”).

The Chairman proposed the motion to pass the following resolution:

“That pursuant to Section 161 of the Companies Act 1967 (the “**Companies Act**”) and Rule 806 of the SGX-ST Catalist Rules, the Directors of the Company be authorised and empowered to:

- (a) (i) allot and issue shares in the capital of the Company (“**Shares**”) whether by way of rights bonus or otherwise; and/or
- (ii) make or grant offers, agreements or options (collectively, “**Instruments**”) that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares,

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit; and

- (b) (notwithstanding the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors of the Company while this Resolution was in force,

provided that:

- (1) the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) to be issued pursuant to this Resolution shall not exceed one hundred per centum (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares (including Shares to be issued in pursuance of the Instruments made or granted pursuant to this Resolution) to be issued other than on a pro rata basis to shareholders of the Company shall not exceed fifty per centum (50%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below);
- (2) (subject to such manner of calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company shall be based on the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time of the passing of this Resolution, after adjusting for:
  - (a) new Shares arising from the conversion or exercise of any convertible securities;
  - (b) new Shares arising from the exercising of share options or vesting of share awards; and
  - (c) any subsequent bonus issue, consolidation or subdivision of Shares,

and, in sub-paragraph (1) above and this sub-paragraph (2), “subsidiary holdings” has the meaning given to it in the Catalist Rules.

Minutes of Annual General Meeting held on 29 April 2026

Adjustments in accordance with sub-paragraph (2)(a) or (2)(b) are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of this Resolution;

- (3) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), the Companies Act and the Constitution, for the time being, of the Company; and
- (4) unless revoked or varied by the Company in a general meeting, such authority shall continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.”

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 7</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	447,721,013	447,721,013	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 7 carried.

#### **Ordinary Resolution 8 – Authority to issue shares under the ISEC Healthcare Share Option Scheme**

Ordinary Resolution 8 was to authorise the Directors to issue shares under the ISEC Healthcare Share Option Scheme.

The Chairman proposed the motion to pass the following resolution:

“That pursuant to Section 161 of the Companies Act, the Directors of the Company be authorised to offer and grant options in accordance with the provisions of the Share Option Scheme and to allot and issue from time to time such number of Shares in the capital of the Company as may be required to be allotted and issued pursuant to the exercise of options under the Share Option Scheme, provided always that the aggregate number of new Shares to be allotted and issued pursuant to the Share Option Scheme, when added to the aggregate number of Shares issued and issuable in respect of all options granted under the Share Option Scheme and any other share option, share incentive, performance share or restricted share plan implemented by the Company, shall not exceed 15% of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company on the day preceding the date of grant of the option, as determined in accordance with the provisions of the Share Option Scheme. Such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.”

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

Minutes of Annual General Meeting held on 29 April 2026

The poll results were tabulated as follows:

<b>Ordinary Resolution 8</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	346,238,864	345,988,864	99.93	250,000	0.07

Based on the results of the poll, the Chairman declared Ordinary Resolution 8 carried.

### **Ordinary Resolution 9 – Authority to issue shares under the ISEC Healthcare Performance Share Plan**

Ordinary Resolution 9 was to authorise the Directors to issue shares under the ISEC Healthcare Performance Share Plan.

The Chairman proposed the motion to pass the following resolution:

“That pursuant to Section 161 of the Companies Act, the Directors of the Company be authorised and empowered to grant awards in accordance with the provisions of the Performance Share Plan and to allot and issue from time to time, such number of Shares in the capital of the Company as may be required to be allotted and issued pursuant to the vesting of awards under the Performance Share Plan, provided always that the aggregate number of Shares issued and issuable in respect of all awards granted under the Performance Share Plan, when added to all Shares issued and issuable in respect of the ISEC Healthcare Share Option Scheme and any other share scheme implemented by the Company for the time being in force, shall not exceed fifteen per centum (15%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) of the Company on the day preceding the date of grant of the award. Such authority shall, unless revoked or varied by the Company in a general meeting, continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier.”

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 9</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	349,182,448	348,932,448	99.93	250,000	0.07

Based on the results of the poll, the Chairman declared Ordinary Resolution 9 carried.

### **Ordinary Resolution 10 – Proposed Renewal of the Share Buyback Mandate**

Ordinary Resolution 10 was to approve the renewal of the Company’s Share Buyback Mandate.

The Chairman proposed the motion to pass the following resolution:

“That

(a) for the purposes of Sections 76C and 76E of the Companies Act, the Directors of the Company be and are hereby authorised to exercise all the powers of the Company to purchase or otherwise acquire Shares not exceeding in aggregate the Prescribed Limit (as hereinafter defined), at such price(s) as may be determined by the Directors of the Company from time to time up to the Maximum Price (as hereinafter defined), whether by way of:

- (i) market purchases transacted on Catalist through the ready market, and which may be transacted through one or more duly licensed stockbrokers appointed by the Company for the purpose of the share buyback (“**Market Purchases**”); and/or
- (ii) off-market purchases effected pursuant to an equal access scheme as defined in Section 76C of the Companies Act (“**Off-Market Purchase**”),

and otherwise in accordance with all other laws and regulations, including but not limited to, the Company’s Constitution, the provisions of the Companies Act and the Catalist Rules as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the “**Share Buyback Mandate**”);

(b) any Share that is purchased or otherwise acquired by the Company pursuant to the Share Buyback Mandate shall, at the discretion of the Directors of the Company, either be cancelled or held in treasury and dealt with in accordance with the Companies Act;

(c) unless varied or revoked by the Company in general meeting, the authority conferred on the Directors of the Company pursuant to the Share Buyback Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the passing of this Resolution and expiring on the earlier of:

- (i) the date on which the next AGM of the Company is held or is required by law to be held;
- (ii) the date on which the purchases or acquisitions of the shares pursuant to the Share Buyback Mandate is carried out to the full extent mandated; or
- (iii) the date on which the authority conferred in the Share Buyback Mandate is varied or revoked by the shareholders in a general meeting,

whichever is the earliest (“**Relevant Period**”);

(d) for purposes of this Resolution:

“**Prescribed Limit**” means 10% of the total number of issued ordinary shares of the Company (“**Shares**”) as at the date of passing of this Resolution unless the Company has, at any time during the Relevant Period, effected a reduction of the share capital of the Company in accordance with the applicable provisions of the Companies Act, in which event the total number of Shares shall be taken to be the total number of Shares as altered (excluding any treasury shares and subsidiary holdings that may be held by the Company from time to time); and

“**Maximum Price**” in relation to a Share to be purchased, means the purchase price (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) not exceeding:

- (i) in the case of a Market Purchase, 105% of the Average Closing Price; and
- (ii) in the case of an Off-Market Purchase pursuant to an equal access scheme, 120% of the Average Closing Price,

where:

- (iii) **“Average Closing Price”** means the average of the closing market prices of a Share over the last five market days, on which transactions in the Shares were recorded, before the day on which the purchase or acquisition of Shares was made, or as the case may be, the day of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted for any corporate action that occurs during the relevant five (5)-day period and the day on which the purchases are made;
  - (iv) **“day of the making of the offer”** means the day on which the Company announces its intention to make an offer for an Off-Market Purchase, stating the purchase price (which shall not be more than the Maximum Price) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase; and
  - (v) **“market day”** means a day on which the SGX-ST is open for trading in securities; and
- (e) any of the Directors of the Company be and are hereby authorised to complete and do all such acts and things (including without limitation, to execute all such documents as may be required and to approve any amendments, alterations or modifications to any documents), as they or he may consider desirable, expedient or necessary to give effect to the transactions contemplated by this Resolution.”

The Meeting was opened to the floor for questions. As there were no questions raised, the Chairman put the resolution to vote by way of poll.

The poll results were tabulated as follows:

<b>Ordinary Resolution 10</b>	<b>Votes Total</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>
	439,877,881	439,877,881	100.00	0	0.00

Based on the results of the poll, the Chairman declared Ordinary Resolution 10 carried.

## **CLOSE OF THE MEETING**

There being no other business, the Chairman declared the Meeting closed at 10.55 a.m..

Confirmed as True Record of Proceedings Held

---

Chong Weng Hoe  
Chairman